Evaluation of platelet parameters and neutrophil/lymphocyte ratio during omalizumab treatment in patients with severe chronic spontaneous urticaria
暂无分享,去创建一个
Ç. Karakükçü | M. Atasoy | Kemal Özyurt | Emin Özlü | A. Avcı | R. Ertaş | M. Akkuş | Ragıp Ertaş
[1] M. Maurer,et al. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change , 2018, Allergy. European Journal of Allergy and Clinical Immunology.
[2] M. Maurer,et al. Increased IgE levels are linked to faster relapse in patients with omalizumab-discontinued chronic spontaneous urticaria. , 2017, The Journal of allergy and clinical immunology.
[3] P. Burchardt,et al. The Role of Hematological Indices in Patients with Acute Coronary Syndrome , 2017, Disease markers.
[4] D. Avcı,et al. Can we use the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and mean platelet volume values for the diagnosis of anterior uveitis in patients with Behcet’s disease? , 2017, Therapeutics and clinical risk management.
[5] K. Rothman,et al. Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma , 2017, The Journal of allergy and clinical immunology.
[6] L. Garcia,et al. Neutrophil lymphocyte ratio in peripheral vascular disease: a review , 2016, Expert review of cardiovascular therapy.
[7] Kemal Özyurt,et al. Adverse Reaction to Omalizumab in Patients with Chronic Urticaria: Flare Up or Ineffectiveness? , 2016, Iranian journal of allergy, asthma, and immunology.
[8] I. Altunay,et al. Serum C-Reactive Protein, Neutrophil-Lymphocyte Ratio and Uric Acid Levels in Chronic Spontaneous Urticaria , 2016 .
[9] A. Aras,et al. Neutrophil–Lymphocyte Ratio Connected to Treatment Options and Inflammation Markers of Ankylosing Spondylitis , 2015, Journal of clinical laboratory analysis.
[10] Michihiro Hide,et al. The EAACI/GA 2 LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update , 2015 .
[11] M. Maurer,et al. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. , 2015, The Journal of allergy and clinical immunology.
[12] J. Prajapati,et al. Association of High Density Lipoprotein with Platelet to Lymphocyte and Neutrophil to Lymphocyte Ratios in Coronary Artery Disease Patients , 2014, Journal of lipids.
[13] T. Zuberbier,et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. , 2014, Allergy.
[14] J. Kasperski,et al. The Association between Platelet Count and Acute Phase Response in Chronic Spontaneous Urticaria , 2014, BioMed research international.
[15] M. Rajappa,et al. Platelet activation in chronic urticaria and its correlation with disease severity , 2014, Platelets.
[16] T. Casale,et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. , 2013, The New England journal of medicine.
[17] R. Gorczynski,et al. Clinical course and side effects of anti-IgE monoclonal antibody in patients with severe persistent asthma. , 2013 .
[18] A. Hartzema,et al. Assessing the association between omalizumab and arteriothrombotic events through spontaneous adverse event reporting , 2012, Journal of asthma and allergy.
[19] M. Leshno,et al. Chronic urticaria and autoimmunity: associations found in a large population study. , 2012, The Journal of allergy and clinical immunology.
[20] J. Mishal,et al. Clinical and laboratory features of antihistamine-resistant chronic idiopathic urticaria. , 2011, Allergy and asthma proceedings.
[21] G. Kitas,et al. Mean platelet volume: a link between thrombosis and inflammation? , 2011, Current pharmaceutical design.
[22] T. Zuberbier,et al. Epidemiology of urticaria: a representative cross‐sectional population survey , 2010, Clinical and experimental dermatology.
[23] J. Mishal,et al. Increased Mean Platelet Volume and C-Reactive Protein Levels in Patients With Chronic Urticaria With a Positive Autologous Serum Skin Test , 2010, The American journal of the medical sciences.
[24] S. Spector,et al. Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic / Spontaneous Urticaria Who Remain Symptomatic on H 1 Antihistamines : A Randomized , Placebo-Controlled Study , 2010 .
[25] E. Gounari,et al. Platelet distribution width: a simple, practical and specific marker of activation of coagulation. , 2010, Hippokratia.
[26] G. Kitas,et al. Mean platelet volume in patients with rheumatoid arthritis: the effect of anti-TNF-alpha therapy , 2010, Rheumatology International.
[27] D. Ledford. Omalizumab: overview of pharmacology and efficacy in asthma , 2009, Expert opinion on biological therapy.
[28] S. Holgate,et al. Safety and tolerability of omalizumab , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[29] H. Schünemann,et al. EAACI/GA2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria , 2006, Allergy.
[30] T. Kawamoto,et al. Relationship between Hemostatic Factors and the Platelet Index in Patients with Ischemic Heart Disease , 2007, Pathophysiology of Haemostasis and Thrombosis.
[31] J. Brittenden,et al. The role of platelets in peripheral vascular disease. , 2003, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.